Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 11/2017

01-11-2017 | Research Article

Hangeshashinto (TJ-14) prevents radiation-induced mucositis by suppressing cyclooxygenase-2 expression and chemotaxis of inflammatory cells

Authors: D. Kamide, T. Yamashita, K. Araki, M. Tomifuji, A. Shiotani

Published in: Clinical and Translational Oncology | Issue 11/2017

Login to get access

Abstract

Purpose

Radiation-induced oral mucositis is the most common side effect of radiotherapy in head and neck cancer; however, effective modalities for its prevention have not been established. In this study, we evaluated the effectiveness of Hangeshashinto (TJ-14), a Japanese herbal medicine, for preventing radiation-induced mucositis and elucidated its effect on inflammatory responses, including inflammatory cell chemotaxis and cyclooxygenase-2 (COX2) expression, in an animal model.

Methods

Syrian hamsters, 8–9 weeks old, were enrolled in this study. Animals were irradiated with a single 40 Gy dose to the buccal mucosa. Hamsters freely received a treatment diet mixed with 2% TJ-14 or a normal diet daily. The therapeutic effect was determined based on the visual mucositis score, body weight, and histological examination of infiltrated neutrophils and COX2 expression.

Results

TJ-14 significantly reduced the severity of mucositis. The percentage with severe mucositis (score ≥3) was 100% in the untreated group and 16.7% in the TJ-14 group (P < 0.05). There was no difference in body weight change between the groups; however, weight gain in the untreated group tended to be suppressed compared to that in the TJ-14 group during the peak period of mucositis. In addition, TJ-14 inhibited the infiltration of neutrophils and COX2 expression in irradiated mucosa (P < 0.05).

Conclusions

TJ-14 reduced the severity of mucositis in an animal model by suppressing the inflammatory response. Because TJ-14 is inexpensive and its safety is established, it is a promising candidate for the standard treatment of radiation-induced mucositis in cancer patients.
Literature
1.
Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081–6.CrossRefPubMed
2.
Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–8.CrossRefPubMed
3.
Trotti A, Bellm L, Epstein J, Frame D, Fuchs H, Gwede C, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66:253–62.CrossRefPubMed
4.
Köstler WJ, Michael H, Catharina W, Christoph ZC. Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. CA Cancer J Clin. 2001;51:290–351.CrossRefPubMed
5.
Russo G, Haddad R, Posner M, Machtay M. Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist. 2008;13:886–98.CrossRefPubMed
6.
Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120:1453–61.CrossRefPubMedPubMedCentral
7.
Finch PW, Rubin JS. Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors. J Natl Cancer Inst. 2006;98:812–24.CrossRefPubMed
8.
Yamashita T, Araki K, Tomifuji M, Kamide D, Tanaka Y, Shiotani A. A traditional Japanese medicine—Hangeshashinto (TJ-14)—alleviates chemoradiation-induced mucositis and improves rates of treatment completion. Support Care Cancer. 2015;23:29–35.CrossRefPubMed
9.
Kono T, Satomi M, Chisato N, Ebisawa Y, Suno M, Asama T, et al. Topical application of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis. World J Oncol. 2010;1:232–5.
10.
Sonis ST, Tracey C, Shklar G, Jenson J, Florine D. An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Path. 1990;69:437–43.CrossRefPubMed
11.
Murphy C, Fey E, Watkins B, Wong V, Rothstein D, Sonis S. Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters. Clin Cancer Res. 2008;14:4292–7.CrossRefPubMed
12.
Pico JL, Avila-Garavito A, Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist. 1998;3:446–51.PubMed
13.
14.
Brock GT, McNish WR, Peters-Golden M. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J Biol Chem. 1999;274:11660–6.CrossRefPubMed
15.
Kuehl F Jr, Egan R. Prostaglandins, arachidonic acid, and inflammation. Science. 1980;210:978–84.CrossRefPubMed
16.
Sonis ST, O’Donnell KE, Popat R, Bragdon C, Phelan S, Cocks D, et al. The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol. 2004;40:170–6.CrossRefPubMed
17.
Lalla RV, Pilbeam CC, Walsh SJ, Sonis ST, Keefe DM, Peterson DE. Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study. Support Care Cancer. 2010;18:95.CrossRefPubMed
18.
Kaneko T, Chiba H, Horie N, Kato T, Kobayashi M, Hashimoto K, et al. Effect of Scutellariae Radix ingredients on prostaglandin E2 production and COX-2 expression by LPS-activated macrophage. In Vivo. 2009;23:577–81.PubMed
19.
Chen YC, Shen SC, Chen LG, Lee TJF, Yang LL. Wogonin, baicalin, and baicalein inhibition of inducible nitric oxide synthase and cyclooxygenase-2 gene expressions induced by nitric oxide synthase inhibitors and lipopolysaccharide. Biochem Pharmacol. 2001;61:1417–27.CrossRefPubMed
20.
Wu P, Zhang Y, Liu Y, Wang X, Guo Z, Zhang Y, et al. Effects of glycyrrhizin on production of vascular aldosterone and corticosterone. Horm Res. 1999;51:189–92.PubMed
21.
Hiai S, Yokoyama H, Oura H, Kawashima Y. Evaluation of corticosterone secretion-inducing activities of ginsenosides and their prosapogenins and sapogenins. Chem Pharm Bull. 1983;31:168–74.CrossRefPubMed
22.
Kase Y, Saitoh K, Ishige A, Komatsu Y. Mechanisms by which Hange-shashin-to reduces prostaglandin E2 levels. Biol Pharm Bull. 1998;21:1277–81.CrossRefPubMed
23.
Amin AH, Subbaiah TV, Abbasi KM. Berberine sulfate: antimicrobial activity, bioassay, and mode of action. Can J Microbiol. 1969;15:1067–76.CrossRefPubMed
24.
Kono T, Kaneko A, Matsumoto C, Miyagi C, Ohbuchi K, Yasuharu M, et al. Multitargeted effects of Hangeshashinto for treatment of chemotherapy-induced oral mucositis on inducible prostaglandin E2 production in human oral keratinocytes. Integr Cancer Ther. 2014;13:435–45.CrossRefPubMed
25.
Ara G, Watkins BA, Zhong H, Hawthorne TR, Karkaria CE, Sonis ST, et al. Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation. Int J Radiat Biol. 2008;84:401–12.CrossRefPubMed
26.
Hatakeyama H, Takahashi H, Oridate N, Kuramoto R, Fujiwara K, Homma K, et al. Hangeshashinto improves the completion rate of chemoradiotherapy and the nutritional status in patients with head and neck cancer. ORL J Otorhinolaryngol Relat Spec. 2015;77:100–8.CrossRefPubMed
Metadata
Title
Hangeshashinto (TJ-14) prevents radiation-induced mucositis by suppressing cyclooxygenase-2 expression and chemotaxis of inflammatory cells
Authors
D. Kamide
T. Yamashita
K. Araki
M. Tomifuji
A. Shiotani
Publication date
01-11-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 11/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1672-8

Other articles of this Issue 11/2017

Clinical and Translational Oncology 11/2017 Go to the issue

Research Article

Long-term cardiovascular complications in stage I seminoma patients

Research Article

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?

Brief Research Article

Gynecological brachytherapy for postoperative endometrial cancer: dosimetric analysis (Ir-192 vs Co-60)

Research Article

The spine instability neoplastic score (SINS) in the assessment of response to radiotherapy for bone metastases

Research Article

Validation of SDM-Q-Doc Questionnaire to measure shared decision-making physician’s perspective in oncology practice

Research Article

A logistic regression model predicting high axillary tumour burden in early breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits